Dr. Euy Sung Moon


Johannes Gutenberg-University Mainz
Department of Chemistry
Duesbergweg 10–14
Room 2221.01.133
55128 Mainz
Phone: +49 6131/39-36200
E-mail: emoon01@uni-mainz.de
. .
2011–2015 Bachelor Studies in Chemistry at JGU Mainz
2014 Bachelor Thesis in the group of Prof. S. R. Waldvogel at JGU Mainz
2016–2018 Master Studies in the Chemistry at JGU Mainz
2016–2017 Research Stay in the group of Dr. J. Brgoch at Univ. of Houston, USA
2018 Master Thesis in the group of Prof. Dr. F. Rösch at JGU Mainz

PhD Studies in the group of Prof. Dr. F. Rösch

Subject: Radiopharmaceutical Chemistry

Since 2022

PostDoc in the group of Prof. Dr. S. R. Waldvogel

Project management, ETOS project

. .
. .

S. Ballal, M. P. Yadav, E. S. Moon, F. Roesch, S. Kumari, S. Agarwal, M. Tripathi, R. K. Sahoo, B. S. Mangu, A. Tupalli, C. Bal, Novel Fibroblast Activation Protein Inhibitor-Based targeted Theranostics for Radioiodine Refractory differentiated Thyroid Cancer Patients: A Pilot Study, Thyroid 2022, 32, 65–77.
[DOI: 10.1089/thy.2021.0412]

S. Ballal, M. P. Yadav, E. S. Moon, V. Kramer, F. Roesch, S. Kumari, C. Bal, First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2, Pharmaceuticals 2021, 14, 1212.
[DOI: 10.3390/ph14121212]

E. S. Moon, S. Ballal, M. P. Yadav, C. Bal, Y. Van Rymenant, S. Stephan, A. Bracke, P. Van der Veken, I. De Meester, F. Roesch, Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: A step to improve tumor uptake and retention time, AJNMMI 2021, 11(6), 476–491.

S. Imlimthan, E. S. Moon, H. Rathke, A. Afshar-oromieh, F. Rösch, A. Rominger, E. Gourni, New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors : A Rational Review and Current Progress, Pharmaceuticals 2021, 14, 1023.
[DOI: 10.3390/ph14101023]

B. Kreppel, M. A. Gonzalez-carmona, G. Feldmann, J. Küppers, E. S. Moon, M. Marinova, F. C. Gaertner, Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours, Nuklearmedizin 2021, 60, 344–354.
[DOI: 10.1055/a-1521-8604]

T. Grus, H. Lahnif, B. Klasen, E. S. Moon, L. Greifenstein, F. Roesch, Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy, Bioconjug. Chem. 2021, 32, 1223–1231.
[DOI: 10.1021/acs.bioconjchem.1c00305]

E. S. Moon, Y. Van Rymenant, S. Battan, J. De Loose, A. Bracke, P. Van der Veken, I. De Meester, F. Roesch, In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi, Molecules 2021, 26, 3482.
[DOI: 10.3390/molecules26123482]

B. Klasen, E. S. Moon, F. Rösch, AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-A''-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions, Nucl. Med. Biol. 2021, 96–97, 80–93.
[DOI: 10.1016/j.nucmedbio.2021.03.007]

F. Rosar, H. Bohnenberger, E. S. Moon, F. Rösch, A. Denig, D. Vincenz-Zörner, M. A. Hoffmann, F. Khreish, S. Ezziddin, M. Schreckenberger, H. G. Buchholz, A. Schaefer-Schuler, Impact of prompt gamma emission of 44Sc on quantification in preclinical and clinical PET systems, Appl. Radiat. Isot. 2021, 170, 1–8.
[DOI: 10.1016/j.apradiso.2021.109599]

M. Hofstetter, E. S. Moon, F. D’Angelo, L. Geissbühler, I. Alberts, A. Afshar-Oromieh, F. Rösch, A. Rominger, E. Gourni, Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist, EJNMMI Radiopharm. Chem. 2020, 5, 29.
[DOI: 10.1186/s41181-020-00115-8]

J. P. Sinnes, U. Bauder-Wüst, M. Schäfer, E. S. Moon, K. Kopka, F. Rösch, 68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues, EJNMMI Radiopharm. Chem. 2020, 5, 28.
[DOI: 10.1186/s41181-020-00107-8]

S. Ballal, M. P. Yadav, E. S. Moon, V. Kramer, F. Roesch, S. Kumari, M. Tripathi, S. T. ArunRaj, S. Sarswat, C. Bal, Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers, Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 1915–1931.
[DOI: 10.1007/s00259-020-05132-y]

S. Ballal, M. P. Yadav, V. Kramer, E. S. Moon, F. Roesch, M. Tripathi, S. Mallick, S. T. ArunRaj, C. Bal, A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy, Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 942–944.
[DOI: 10.1007/s00259-020-04990-w]

E. S. Moon, F. Elvas, V. Gwendolyn, S. De Lombaerde, C. Vangestel, S. De Bruycker, A. Bracke, E. Eppard, L. Greifenstein, B. Klasen, V. Kramer, S. Staelens, I. De Meester, P. Van der Veken, F. Rösch, Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators, EJNMMI Radiopharm. Chem. 2020, 5, 19.
[DOI: 10.1186/s41181-020-00102-z]

B. Kreppel, F. Gärtner, M. Marinova, U. Attenberger, M. Meisenheimer, M. Toma, G. Kristiansen, G. Feldmann, E. S. Moon, F. Roesch, P. Van der Veken, M. Essler, [68Ga]Ga-DATA5m.SA.FAPi PET/CT: Specific Tracer-uptake in Focal Nodular Hyperplasia and potential Role in Liver Tumor Imaging, Nuklearmedizin 2020, 59, 387–389.
[DOI: 10.1055/a-1164-5667]